Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • hepatitis C

    Tag: hepatitis c

    You Searched For "hepatitis C"
    Merck loses bid to revive over Rs 18 crore patent verdict against Gilead

    Merck loses bid to revive over Rs 18 crore patent verdict against Gilead

    Farhat Nasim31 Oct 2019 3:27 PM IST
    In 2016, a jury returned a verdict that Gilead Science's hepatitis C drugs Sovaldi and Harvoni infringed the patent, which Merck acquired when it...
    Laurus Labs to acquire subsidiary of ASPEN Pharmacare

    Laurus Labs to acquire subsidiary of ASPEN Pharmacare

    Farhat Nasim24 Sept 2019 9:30 AM IST
    "The completion of conditions precedent, by way of cash consideration of ZAR 75,000, the Pharmaceutical company said in a statement here. The...
    Gilead licenses respiratory, herpes antiviral research programs from Novartis

    Gilead licenses respiratory, herpes antiviral research programs from Novartis

    Medical Dialogues Bureau23 July 2019 9:15 AM IST
    Under the agreement, Gilead will acquire exclusive global rights to develop and commercialize novel small molecules against three undisclosed targets....
    Gilead to raise stake in Belgian Biotech Galapagos in USD 5.1 billion deal: Report

    Gilead to raise stake in Belgian Biotech Galapagos in USD 5.1 billion deal: Report

    Medical Dialogues Bureau15 July 2019 9:30 AM IST
    The deal is the largest Gilead has executed since new Chief Executive Officer Dan O'Day took the reins in March as he attempts to bolster the San...
    CDSCO releases Risk classification of newly notified Medical Devices, IVDs; Details

    CDSCO releases Risk classification of newly notified Medical Devices, IVDs; Details

    Meghna A Singhania18 May 2019 2:08 PM IST
    New Delhi: Through a recent notification, country's central medical device regulator, the Central Drugs Standards Control Organization (CDSCO) has...
    AbbVie wins USFDA nod for Mavyret to treat HCV genotypes in pediatric patients

    AbbVie wins USFDA nod for Mavyret to treat HCV genotypes in pediatric patients

    Farhat Nasim3 May 2019 9:10 AM IST
    New Delhi: AbbVie Inc. recently won the U.S. Food and Drug Administration (USFDA) approval for Mavyret (glecaprevir and pibrentasvir) tablets to treat...
    US court upholds dismissal of 200 million dollars Merck verdict against Gilead

    US court upholds dismissal of 200 million dollars Merck verdict against Gilead

    Ruby Khatun Khatun27 April 2018 9:30 AM IST
    A U.S. appeals court affirmed a ruling that pharmaceutical company Merck & Co dishonestly obtained patent rights and was not entitled to collect a...
    CDSCO releases Risk classification of Medical Devices and IVDs

    CDSCO releases Risk classification of Medical Devices and IVDs

    savita thakur thakur8 Nov 2017 3:24 PM IST
    Through a recent notification, Drugs Controller General (India), Directorate General of Health Services, India's central medical device regulator, the...
    Merck to stop development of hepatitis C treatments

    Merck to stop development of hepatitis C treatments

    Ruby Khatun Khatun4 Oct 2017 10:20 AM IST
    U.S. drugmaker Merck & Co said on Friday it would discontinue developing an experimental drug combination for chronic hepatitis C, as competition...
    Johnson and Johnson arm Janssen to discontinue Hepatitis C development program

    Johnson and Johnson arm Janssen to discontinue Hepatitis C development program

    Ruby Khatun Khatun14 Sept 2017 10:02 AM IST
    CORK, Ireland: Janssen Sciences Ireland UC (Janssen), announced a strategic decision to discontinue further development of the investigational...
    Co-Diagnostics to sign purchase agreement with MEDCIS Pathlabs

    Co-Diagnostics to sign purchase agreement with MEDCIS Pathlabs

    Ruby Khatun Khatun9 Sept 2017 9:34 AM IST
    SANDY, Utah: Co-Diagnostics, Inc. ("Co-Diagnostics" or the "Company"), a molecular diagnostics company with a unique, proprietary platform for the...
    FDA approves Mavyret for Hepatitis C

    FDA approves Mavyret for Hepatitis C

    Ruby Khatun Khatun10 Aug 2017 9:45 AM IST
    The U.S. Food and Drug Administration (FDA) approved Mavyret (glecaprevir and pibrentasvir) to treat adults with chronic hepatitis C virus (HCV)...
    Next

    Popular Stories

    • Email: info@medicaldialogues.in
    • Phone: 011 - 4372 0751

    Website Last Updated On : 13 Oct 2022 5:14 AM GMT
    Company
    • About Us
    • Contact Us
    • Our Team
    • Reach our Editor
    • Feedback
    • Submit Article
    Ads & Legal
    • Advertise
    • Advertise Policy
    • Terms and Conditions
    • Privacy Policy
    • Editorial Policy
    • Comments Policy
    • Disclamier
    Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

    Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

    © 2025 - Medical Dialogues. All Rights Reserved.
    Powered By: Hocalwire
    X
    We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok